Cyclophosphamide-induced severe acute hepatitis in a rheumatic disease: case-based review

ÜSKÜDAR CANSU D., ÖZTAŞ E., YILMAZ E., KORKMAZ C.

RHEUMATOLOGY INTERNATIONAL, cilt.39, sa.2, ss.377-385, 2019 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Derleme
  • Cilt numarası: 39 Sayı: 2
  • Basım Tarihi: 2019
  • Doi Numarası: 10.1007/s00296-018-4189-8
  • Dergi Adı: RHEUMATOLOGY INTERNATIONAL
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.377-385
  • Anahtar Kelimeler: Cyclophosphamide, Hepatotoxicity, Severe acute hepatitis, Lupus, HEPATOTOXICITY, PATIENT, METABOLISM
  • Eskişehir Osmangazi Üniversitesi Adresli: Evet

Özet

In rheumatology practice, the risk of hepatotoxicity from medications, including non-steroidal anti-inflammatory drugs, notably, and methotrexate, sulfasalazine, leflunomide, and azathioprine is highly recognized by the rheumatologists. On the other hand, hepatotoxicity is neither a commonly expected nor a well-known side effect of cyclophosphamide (CYC) which is particularly used for vital organ involvements in systemic lupus erythematosus (SLE) and systemic vasculitis. Here we reported a 19-year-old case of SLE who, while on oral CYC treatment of 100 mg/day, was detected to have asymptomatic liver enzyme elevation and then developed acute hepatitis due to intravenously administered high-dose (1 g) CYC for neuro-lupus. Results of liver biopsy indicated drug-related toxicity. We discussed here with the other, although rare, cases available in the literature with an attempt to highlight the risk of hepatotoxicity and acute hepatitis due to CYC.